title: Haloperidol versus haloperidol plus ondansetron for the prophylaxis of postoperative nausea and vomiting after ophthalmologic surgery.
abstract: BACKGROUND
  In this prospective, randomized, and double-blinded study we investigated the efficacy of haloperidol (10 microg/kg) and the combination of haloperidol (10 microg/kg) with ondansetron (0.1 mg/kg) for the prophylaxis of postoperative nausea and vomiting (PONV) after ophthalmologic surgery.
  
  
  METHODS
  60 patients (ASA status 1-3) with risk factors for PONV (female, non-smoker, motion sickness or PONV in history, opioids for postoperative analgesia) undergoing retinal or strabismus surgery were included into the study and randomised to the haloperidol group (H-Group) or the haloperidol-ondansetron group (H/O-Group). 20 min before the end of anaesthesia the study medication was given. Nausea, vomiting, pain scores, and adverse events were assessed postoperatively over 24 h.
  
  
  RESULTS
  The incidence of PONV was lower for the H/O-Group (23 vs. 57% for the H-Group). Especially the incidence of vomiting was reduced for the H/O-Group (7 vs. 27% in the H-Group). No significant differences could be detected regarding adverse events.
  
  
  CONCLUSIONS
  The single use of haloperidol for the prophylaxis of PONV is doubtful. Better results were obtained with the combination therapy of haloperidol with ondansetron, especially for vomiting.
authors.affiliation: Department of Anaesthesiology, University of Cologne, Cologne, Germany.
authors.forename: Oguzhan
authors.initials: O
authors.lastname: Dagtekin
authors.forename: Philip
authors.initials: P
authors.lastname: Wiese
authors.forename: Karsten
authors.initials: K
authors.lastname: Wolter
authors.forename: Manuel M
authors.initials: MM
authors.lastname: Hermann
authors.forename: Christian
authors.initials: C
authors.lastname: Pietruck
authors.forename: Sandra
authors.initials: S
authors.lastname: Kampe
mesh_terms: D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D017294:Ondansetron / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D013508:Ophthalmologic Surgical Procedures / Q000009:adverse effects*; D010147:Pain Measurement; D010149:Postoperative Pain / Q000188:drug therapy; D020250:Postoperative Nausea and Vomiting / Q000517:prevention & control*; D012307:Risk Factors; D013997:Time Factors
chemical_list: D017294:Ondansetron; D006220:Haloperidol